Healthcare Value Capital Lowers stake in Albany Molecular Research (AMRI)

Albany Molecular Research (AMRI) : Healthcare Value Capital reduced its stake in Albany Molecular Research by 24.85% during the most recent quarter end. The investment management company now holds a total of 302,400 shares of Albany Molecular Research which is valued at $4,505,760 after selling 100,000 shares in Albany Molecular Research , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Albany Molecular Research makes up approximately 7.10% of Healthcare Value Capital’s portfolio.

Other Hedge Funds, Including , Kennedy Capital Management boosted its stake in AMRI in the latest quarter, The investment management firm added 4,491 additional shares and now holds a total of 46,248 shares of Albany Molecular Research which is valued at $689,095. Albany Molecular Research makes up approx 0.01% of Kennedy Capital Management’s portfolio.Denver Investment Advisors reduced its stake in AMRI by selling 1,926 shares or 15.62% in the most recent quarter. The Hedge Fund company now holds 10,406 shares of AMRI which is valued at $155,882. Albany Molecular Research makes up approx 0.01% of Denver Investment Advisors’s portfolio.Ngam Advisors boosted its stake in AMRI in the latest quarter, The investment management firm added 5,831 additional shares and now holds a total of 171,297 shares of Albany Molecular Research which is valued at $2,452,973. Albany Molecular Research makes up approx 0.03% of Ngam Advisors’s portfolio.

Albany Molecular Research closed down -0.11 points or -0.74% at $14.71 with 2,98,447 shares getting traded on Thursday. Post opening the session at $14.81, the shares hit an intraday low of $14.55 and an intraday high of $14.85 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

Albany Molecular Research Inc. is a global contract research and manufacturing organization providing drug discovery development and manufacturing services. The Company operates in three business segments: Discovery and Development Services (DDS) API and Drug Product. The Company offers a portfolio of services from target identification tools to investigational new drug (IND) enabling activities. The Company’s manufacturing facilities are situated in various locations in the United States Europe and Asia. The Company provides state-of-the-art facilities and solutions to deliver integrated pharmaceutical drug development programs and services including process research and development pre-formulation and formulation development good laboratory practices (GLP) bioanalytical and separation sciences.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *